Neophore Revenue and Competitors
Estimated Revenue & Valuation
- Neophore's estimated annual revenue is currently $3.1M per year.
- Neophore's estimated revenue per employee is $155,000
Employee Data
- Neophore has 20 Employees.
- Neophore grew their employee count by 11% last year.
Neophore's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP, Drug Discovery | Reveal Email/Phone |
2 | Chairman, NeoPhore | Reveal Email/Phone |
3 | Principal Scientist - Biology | Reveal Email/Phone |
Neophore Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Neophore?
NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
keywords:N/A
N/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neophore News
2022-04-06 - Aberrant R-loop-induced replication stress in MED12-mutant ...
Julian Blagg (NeoPhore, LTD and The Institute of Cancer Research, London, UK) for the kind gift of CCT251545. Funding. This work was supported...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 20 | -9% | $69M |
#2 | $2.9M | 20 | N/A | N/A |
#3 | $1.5M | 20 | -47% | N/A |
#4 | $3.1M | 20 | 11% | N/A |
#5 | $2M | 20 | -13% | N/A |